MA32555B1 - Composes de pyrrolopyrimidine et leurs utilisations - Google Patents

Composes de pyrrolopyrimidine et leurs utilisations

Info

Publication number
MA32555B1
MA32555B1 MA33606A MA33606A MA32555B1 MA 32555 B1 MA32555 B1 MA 32555B1 MA 33606 A MA33606 A MA 33606A MA 33606 A MA33606 A MA 33606A MA 32555 B1 MA32555 B1 MA 32555B1
Authority
MA
Morocco
Prior art keywords
compounds
protein kinases
relates
pyrrolopyrimidine compounds
cdk8
Prior art date
Application number
MA33606A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Clinton A Brooks
Miles Stuart Congreve
Claudio Dagostin
Gilbert Besong
Christopher Thomas Brain
Guo He
Ying Hou
Steven Howard
Yue Li
Yipin Lu
Paul Mortenson
Troy Smith
Moo Sung
Steven Woodhead
Wojciech Wrona
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32555(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of MA32555B1 publication Critical patent/MA32555B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA33606A 2008-08-22 2011-02-11 Composes de pyrrolopyrimidine et leurs utilisations MA32555B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22
PCT/EP2009/060793 WO2010020675A1 (en) 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as cdk inhibitors

Publications (1)

Publication Number Publication Date
MA32555B1 true MA32555B1 (fr) 2011-08-01

Family

ID=41171100

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33606A MA32555B1 (fr) 2008-08-22 2011-02-11 Composes de pyrrolopyrimidine et leurs utilisations

Country Status (48)

Country Link
US (8) US8685980B2 (cg-RX-API-DMAC7.html)
EP (2) EP2331547B1 (cg-RX-API-DMAC7.html)
JP (2) JP5560496B2 (cg-RX-API-DMAC7.html)
KR (2) KR20130140222A (cg-RX-API-DMAC7.html)
CN (2) CN102186856B (cg-RX-API-DMAC7.html)
AR (2) AR073116A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009284098B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917791B1 (cg-RX-API-DMAC7.html)
CA (1) CA2734802C (cg-RX-API-DMAC7.html)
CL (1) CL2011000306A1 (cg-RX-API-DMAC7.html)
CO (1) CO6341561A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110101A (cg-RX-API-DMAC7.html)
CU (1) CU24062B1 (cg-RX-API-DMAC7.html)
CY (2) CY1115703T1 (cg-RX-API-DMAC7.html)
DK (1) DK2331547T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000057A (cg-RX-API-DMAC7.html)
EA (1) EA019094B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010843A (cg-RX-API-DMAC7.html)
ES (1) ES2522346T3 (cg-RX-API-DMAC7.html)
FR (1) FR17C1059I2 (cg-RX-API-DMAC7.html)
GE (1) GEP20135785B (cg-RX-API-DMAC7.html)
HN (1) HN2011000542A (cg-RX-API-DMAC7.html)
HR (1) HRP20141018T1 (cg-RX-API-DMAC7.html)
HU (1) HUS1700051I1 (cg-RX-API-DMAC7.html)
IL (1) IL211164A (cg-RX-API-DMAC7.html)
JO (1) JO2924B1 (cg-RX-API-DMAC7.html)
LT (1) LTC2331547I2 (cg-RX-API-DMAC7.html)
LU (1) LUC00048I2 (cg-RX-API-DMAC7.html)
MA (1) MA32555B1 (cg-RX-API-DMAC7.html)
ME (1) ME01282B (cg-RX-API-DMAC7.html)
MX (1) MX2011001879A (cg-RX-API-DMAC7.html)
MY (1) MY150560A (cg-RX-API-DMAC7.html)
NI (1) NI201100042A (cg-RX-API-DMAC7.html)
NL (1) NL300909I2 (cg-RX-API-DMAC7.html)
NO (1) NO2017059I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ591176A (cg-RX-API-DMAC7.html)
PE (1) PE20110419A1 (cg-RX-API-DMAC7.html)
PL (1) PL2331547T3 (cg-RX-API-DMAC7.html)
PT (1) PT2331547E (cg-RX-API-DMAC7.html)
RS (1) RS53574B1 (cg-RX-API-DMAC7.html)
SI (1) SI2331547T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500017B (cg-RX-API-DMAC7.html)
TN (1) TN2011000062A1 (cg-RX-API-DMAC7.html)
TW (1) TWI468409B (cg-RX-API-DMAC7.html)
UA (1) UA103628C2 (cg-RX-API-DMAC7.html)
UY (2) UY38935A (cg-RX-API-DMAC7.html)
WO (1) WO2010020675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100994B (cg-RX-API-DMAC7.html)

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331547B1 (en) 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
EP3718560A3 (en) 2009-05-13 2020-12-09 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
RU2589696C2 (ru) * 2010-04-13 2016-07-10 Новартис Аг КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА
EP2606343A4 (en) 2010-08-18 2017-08-16 Life Technologies Corporation Chemical coating of microwell for electrochemical detection device
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR102186969B1 (ko) * 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AU2011329763A1 (en) 2010-11-17 2013-05-09 Brigham And Women's Hospital Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CA2840754A1 (en) 2011-07-01 2013-01-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CA2840620A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CA3163776A1 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP2959013A2 (en) 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
CA2901929A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
MX2015012432A (es) 2013-03-13 2016-02-05 Abbvie Inc Inhibidores piridinicos de la cinasa cdk9.
AR101528A1 (es) 2013-03-14 2016-12-28 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
US9346813B2 (en) 2013-03-14 2016-05-24 Abbvie Inc. Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2014144847A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2014144596A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
CN105209073A (zh) 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
HUE057061T2 (hu) 2013-08-14 2022-04-28 Novartis Ag Kombinációs terápia rák kezelésére
EP3038652B1 (en) * 2013-08-28 2018-03-21 Novartis AG Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW201605857A (zh) * 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
WO2015061407A1 (en) * 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
KR20160090814A (ko) * 2013-11-27 2016-08-01 노파르티스 아게 Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
ES3033810T3 (en) * 2013-12-20 2025-08-08 Biomed Valley Discoveries Inc Cancer treatments using combinations of cdk and erk inhibitors
RU2684106C2 (ru) * 2013-12-23 2019-04-04 Новартис Аг Фармацевтические комбинации
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
JP6263269B2 (ja) * 2013-12-31 2018-01-17 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
CA2950330C (en) * 2014-05-28 2019-04-30 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
EP3218005B1 (en) 2014-11-12 2023-01-04 Seagen Inc. Glycan-interacting compounds and methods of use
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
WO2016091221A1 (zh) * 2014-12-12 2016-06-16 苏州晶云药物科技有限公司 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
CR20170410A (es) 2015-03-10 2017-11-08 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon"
EP3273959A1 (en) * 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN106146515B (zh) 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
RU2695337C2 (ru) 2015-05-29 2019-07-23 Тейдзин Фарма Лимитед ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ
CN105037236B (zh) * 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017037574A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
JP2018528952A (ja) 2015-08-28 2018-10-04 ノバルティス アーゲー Ｐｉ３ｋ阻害剤のアルペリシブおよびｃｄｋ４／６阻害剤のリボシクリブを含む医薬組合せ、ならびにがんの治療／予防におけるその使用
US20180243304A1 (en) * 2015-08-28 2018-08-30 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP7066613B2 (ja) 2015-11-12 2022-05-13 シージェン インコーポレイテッド グリカン相互作用化合物および使用方法
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
EP3434676B1 (en) * 2016-03-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
AU2017254708B2 (en) * 2016-04-22 2021-09-16 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017211245A1 (zh) * 2016-06-06 2017-12-14 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
JP7106462B2 (ja) 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3503923B1 (en) 2016-08-23 2023-10-04 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3804724B1 (en) 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3541391A4 (en) 2016-11-17 2020-06-17 The University of North Carolina at Chapel Hill ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF PREPARING AND USING THE SAME
SI3546456T1 (sl) 2016-11-28 2022-04-29 Teijin Pharma Limited Kristal derivata pirido(3,4-D)pirimidina ali njegovega solvata
JP6785876B2 (ja) 2016-11-28 2020-11-18 帝人ファーマ株式会社 ピリド［３，４−ｄ］ピリミジン誘導体及びその薬学的に許容される塩
EP3548030A4 (en) 2016-12-05 2020-08-12 G1 Therapeutics, Inc. PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC DIETS
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
EP3573619A4 (en) * 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
KR102517650B1 (ko) 2017-03-16 2023-04-05 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암의 치료를 위한 조합물 요법
SMT202400385T1 (it) 2017-03-23 2024-11-15 Jacobio Pharmaceuticals Co Ltd Nuovi derivati eterociclici utili come inibitori di shp2
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
KR102641827B1 (ko) 2017-05-02 2024-03-04 노파르티스 아게 병용 요법
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
KR20200036879A (ko) 2017-08-03 2020-04-07 노파르티스 아게 3세대 egfr 타이로신 키나아제 억제제 및 사이클린 d 키나아제 억제제의 치료적 조합물
KR102715956B1 (ko) 2017-08-25 2024-10-10 아시아 케미컬 인더스트리스 리미티드 리보시클립 염 및 이의 고상 형태
ES3049655T3 (en) 2017-08-31 2025-12-17 Novartis Ag Methods of selecting a treatment for breast cancer patients
CN111164085B (zh) * 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
WO2019082143A1 (en) 2017-10-27 2019-05-02 Fresenius Kabi Oncology Ltd. IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
US11667651B2 (en) * 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US10519136B2 (en) * 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
JP2021509680A (ja) 2018-01-08 2021-04-01 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｇ１ｔ３８の優れた投与レジメン
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3746072B1 (en) * 2018-01-29 2023-04-12 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3043066A1 (en) 2018-05-14 2019-11-14 Apotex Inc. Processes for the preparation of ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ES3030736T3 (en) 2018-07-27 2025-07-01 California Inst Of Techn Cdk inhibitors and uses thereof
EP3836909A4 (en) 2018-08-13 2022-07-27 Beijing Percans Oncology Co. Ltd. BIOMARKERS FOR CANCER THERAPY
EP3840756B1 (en) 2018-08-24 2025-11-05 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
AU2019338032A1 (en) * 2018-09-13 2021-05-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
AU2019413360B2 (en) * 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
KR20210119444A (ko) 2019-01-23 2021-10-05 노파르티스 아게 7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태
TWI831916B (zh) 2019-02-12 2024-02-11 瑞士商諾華公司 包含tno155和瑞博西尼之藥物組合
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
AU2020269469A1 (en) 2019-05-05 2021-12-09 Genentech, Inc. CDK inhibitors
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
AU2020279230A1 (en) 2019-05-20 2021-12-02 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
DK3980411T3 (da) * 2019-06-04 2025-10-13 Step Pharma S A S N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP7657792B2 (ja) * 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7681599B2 (ja) 2019-12-16 2025-05-22 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
SI4077307T1 (sl) 2019-12-18 2025-07-31 Crinetics Pharmaceuticals, Inc. Antagonisti gem-disubstituiranega piperidinskega receptorja melanokortina podtipa 2 (mc2r) in njihova uporaba
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
EP4081518A4 (en) 2019-12-23 2023-12-27 Accutar Biotechnology, Inc. COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER
US12466829B2 (en) 2019-12-23 2025-11-11 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CN114245753A (zh) * 2020-03-27 2022-03-25 江苏康宁杰瑞生物制药有限公司 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
US20230192703A1 (en) * 2020-05-12 2023-06-22 Suzhou Alphama Biotechnology Co., Ltd. Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof
EP4149472A1 (en) 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
JP7451765B2 (ja) * 2020-05-12 2024-03-18 蘇州阿尓脈生物科技有限公司 Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CA3185467A1 (en) * 2020-06-11 2021-12-16 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2022197798A1 (en) 2021-03-19 2022-09-22 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2022207788A2 (en) 2021-04-01 2022-10-06 Krka, D.D., Novo Mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4333847A1 (en) 2021-05-05 2024-03-13 Novartis AG Compounds and compositions for the treatment of mpnst
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4370126A4 (en) 2021-07-16 2025-05-28 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
US12350276B2 (en) 2021-07-26 2025-07-08 Celcuity Inc. Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
KR20240041340A (ko) * 2021-07-27 2024-03-29 보로노이 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
CA3247849A1 (en) * 2022-04-08 2023-10-12 Baerenkraft Therapeutics, Llc Cdk9 inhibitors
KR20250002426A (ko) 2022-04-08 2025-01-07 바이오렉시스 테라퓨틱스, 인크. Cdk9 억제제
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
CN119604315A (zh) 2022-05-20 2025-03-11 诺华股份有限公司 Epha2 bcl-xl抑制剂抗体-药物缀合物及其使用方法
CA3266061A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. DOSING REGIMEN BASED ON ESTROGEN RECEPTOR DEGRADING AGENTS
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
AU2024269592A1 (en) 2023-05-05 2025-12-18 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025080628A1 (en) * 2023-10-10 2025-04-17 Biolexis Therapeutics, Inc. Bifunctional protac and molecular glue compounds and methods of use thereof
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
US20250319032A1 (en) 2024-04-15 2025-10-16 Novartis Ag Pharmaceutical compositions of ribociclib
WO2025235331A1 (en) * 2024-05-07 2025-11-13 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN120441576B (zh) * 2025-07-08 2025-09-26 山东大学 一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
CN120483984B (zh) * 2025-07-09 2025-10-10 山东大学 一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
KR100669578B1 (ko) * 2002-01-22 2007-01-15 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
BR0308232A (pt) 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas
CA2497440C (en) 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
CA2512646A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
AU2004270713A1 (en) 2003-09-05 2005-03-17 Aventis Pharmaceuticals Inc. Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EP1725562A1 (en) 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd Pyrrolopyrimidine derivatives
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP1963273A2 (en) 2005-12-22 2008-09-03 Wyeth a Corporation of the State of Delaware Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2646429A1 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN101981036B (zh) * 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
EP2331547B1 (en) * 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
RU2589696C2 (ru) 2010-04-13 2016-07-10 Новартис Аг КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА

Also Published As

Publication number Publication date
EP2716643A1 (en) 2014-04-09
MX2011001879A (es) 2011-03-29
KR101353857B1 (ko) 2014-01-21
CN102186856A (zh) 2011-09-14
CR20110101A (es) 2011-06-09
BRPI0917791B1 (pt) 2022-03-22
JP2012500785A (ja) 2012-01-12
US20140135312A1 (en) 2014-05-15
IL211164A0 (en) 2011-04-28
EP2331547B1 (en) 2014-07-30
EA201100355A8 (ru) 2013-09-30
AR111763A2 (es) 2019-08-14
DK2331547T3 (da) 2014-11-03
JP2014129361A (ja) 2014-07-10
US20210253578A1 (en) 2021-08-19
UY38935A (es) 2020-12-31
PT2331547E (pt) 2014-10-29
PL2331547T3 (pl) 2015-01-30
CY2017042I1 (el) 2018-04-04
JP5882371B2 (ja) 2016-03-09
HK1156625A1 (en) 2012-06-15
CA2734802E (en) 2010-02-25
US20110152244A1 (en) 2011-06-23
ECSP11010843A (es) 2011-05-31
SMT201500017B (it) 2015-03-05
FR17C1059I2 (fr) 2019-01-11
US20100105653A1 (en) 2010-04-29
TWI468409B (zh) 2015-01-11
CY2017042I2 (el) 2018-04-04
KR20130140222A (ko) 2013-12-23
UA103628C2 (en) 2013-11-11
EA201100355A1 (ru) 2011-10-31
CN103788100A (zh) 2014-05-14
HRP20141018T1 (hr) 2015-02-13
US20240043428A1 (en) 2024-02-08
TW201014858A (en) 2010-04-16
CL2011000306A1 (es) 2011-06-24
EA019094B1 (ru) 2014-01-30
LUC00048I2 (cg-RX-API-DMAC7.html) 2018-01-10
RS53574B1 (sr) 2015-02-27
JP5560496B2 (ja) 2014-07-30
US20170183352A1 (en) 2017-06-29
EP2331547A1 (en) 2011-06-15
HUS1700051I1 (hu) 2017-12-28
ZA201100994B (en) 2011-12-28
US20130184285A1 (en) 2013-07-18
ES2522346T3 (es) 2014-11-14
KR20110052713A (ko) 2011-05-18
WO2010020675A1 (en) 2010-02-25
CO6341561A2 (es) 2011-11-21
HN2011000542A (es) 2013-10-17
BRPI0917791A2 (pt) 2019-08-13
DOP2011000057A (es) 2015-11-15
LUC00048I1 (cg-RX-API-DMAC7.html) 2017-11-15
AR073116A1 (es) 2010-10-13
NO2017059I1 (no) 2017-11-13
CU24062B1 (es) 2014-12-26
FR17C1059I1 (cg-RX-API-DMAC7.html) 2018-02-16
JO2924B1 (en) 2015-09-15
US8962630B2 (en) 2015-02-24
IL211164A (en) 2016-09-29
NL300909I2 (nl) 2017-12-19
LTPA2017039I1 (lt) 2017-12-11
TN2011000062A1 (en) 2012-09-05
SI2331547T1 (sl) 2014-11-28
PE20110419A1 (es) 2011-07-13
LTC2331547I2 (lt) 2018-09-10
US20180155351A1 (en) 2018-06-07
NI201100042A (es) 2011-08-09
US8415355B2 (en) 2013-04-09
GEP20135785B (en) 2013-03-11
CU20110040A7 (es) 2011-12-28
MY150560A (en) 2014-01-30
UY32067A (es) 2010-03-26
CA2734802A1 (en) 2010-02-25
NZ591176A (en) 2012-11-30
CY1115703T1 (el) 2017-01-25
ME01282B (me) 2013-06-20
US8685980B2 (en) 2014-04-01
AU2009284098A1 (en) 2010-02-25
CN102186856B (zh) 2014-09-24
NO2017059I2 (no) 2017-11-13
US9416136B2 (en) 2016-08-16
AU2009284098B2 (en) 2012-03-29
CA2734802C (en) 2016-05-31
NL300909I1 (cg-RX-API-DMAC7.html) 2017-11-10

Similar Documents

Publication Publication Date Title
MA32555B1 (fr) Composes de pyrrolopyrimidine et leurs utilisations
WO2008079933A3 (en) Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
Palomo et al. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)
Li et al. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP‐BEZ235 in renal cell carcinoma cells
MA37711A1 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NZ724323A (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
EA201101666A1 (ru) 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
EA201691862A2 (ru) Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
MX2019013429A (es) Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de celulas b y metodos de uso de las mismas.
PH12015502053A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
MX2008005814A (es) Aminopirimidinas utiles como inhibidores de cinasa.
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
SG165413A1 (en) Pecam-1 genotype
Block Replication protein A and the DNA-dependent protein kinase: Targets and regulators of the DNA damage response.
MA38056B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
HN2001000078A (es) Compuestos, composiciones farmaceuticas y metodos para inhibir kinasas proteinicas solicitante:agouron pharmaceuticals, inc. pais: estados unidos de america.